Navigation Links
3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results

3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results -- SHENYANG, China, Oct. 18 /PRNewswire-Asia-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results


SHENYANG, China, Oct. 18 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited financial results for the third quarter ended September 30, 2010 after the Nasdaq Stock Exchange closes on Monday, November 15, 2010 at 8:00pm (Eastern).

Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00am (Pacific) / 8:00am (Eastern) / 9:00pm (Beijing/Hong Kong) on Tuesday, November 16, 2010 to discuss its 2010 third quarter financial results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 18843960 Local dial-in: China landline 800-819-0121 China mobile 400-620-8038 Hong Kong 852-2475-0994 International toll-free dial-in: Hong Kong 800930346 United Kingdom 080-8234-6646 United States 1-866-519-4004 International toll dial-in: 65 6723 9381 Replay - Conference ID: 18843960

A telephone replay will be available two hours after the call until November 22, 2010, at:

International dial-in: 61-2-8235-5000 United States dial-in: 1-866-214-5335


A live webcast of the conference will be available on the investor relations page of 3SBio's website at and at . A replay of the webcast will be available within one hour after the conclusion of the call.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 500 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see for more information.

Investor Contacts Bo Tan Chief Financial Officer 3SBio Inc. Tel: +86-24-2581-1820 Email: Tom Folinsbee Director of Investor Relations 3SBio Inc. Tel: +852-8191-6991 Email:

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Announces Partial Conversion of Isotechnika Debenture
2. 3SBio Announces Investor Conference Schedule
3. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
4. 3SBio Inc. Announces Results of Annual General Meeting
5. FDA Schedules Third Orphan Drug Workshop for Nov. 4-5, 2010
6. Varian Medical Systems Schedules Fourth Quarter FY2010 News Release and Conference Call
7. Misonix Schedules Fourth Quarter and Fiscal 2010 Financial Results Conference Call; September 28, 2010 at 4:30 p.m. Eastern
8. Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results
9. Varian Medical Systems Schedules Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010
10. Sunridge Schedules European Meetings
11. Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010
Post Your Comments:
(Date:12/1/2015)... WellStar Health System has signed a definitive ... Tenet Healthcare,s five metro Atlanta ... move following the conclusion of the due diligence period. ... and patient safety programs that have resulted in increased ... --> --> With ...
(Date:12/1/2015)... 1, 2015   Nottingham Spirk , a ... the publication of a free whitepaper , ... Market". The whitepaper gives medical product companies, pharmaceutical ... this lucrative segment. Nottingham Spirk ... manage their own health, save money (i.e., fewer ...
(Date:12/1/2015)... WASHINGTON , Dec. 1, 2015 A federal ... motion to dismiss a lawsuit filed by the Pharmaceutical ... Arkansas 900, a new law that forces employers ... Arkansas must now defend ... consumers," said PCMA President and CEO Mark Merritt . ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today ... Golden Bridge Business Awards under the New Products and Services category for its ... sample management software that helps labs organize data and track samples ...
(Date:12/1/2015)... ... 01, 2015 , ... The workstation boundaries for imaging specialists ... Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated medical image display, debuting ... December 4, 2015. , MED-TAB is expected to change teleradiology because for ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of people ... Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. “Hollister ... free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed our ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
Breaking Medicine News(10 mins):